Journal article
Preparation and characterization of a recombinant humanized single- chain Fv antibody/human interleukin-2 fusion protein directed against the HER-2/neu (c-erbB2) proto-oncogene product, p185
Abstract
High dose recombinant human interleukin 2 (rhIL-2) therapy has been used in the treatment of established tumors in both animal models and patients with advanced melanoma or renal carcinoma. However, because high dose rhIL-2 therapy causes severe systemic toxicity in normal tissues, its clinical use has been limited. Therefore, targeting interleukin-2 (IL-2) to the tumor site should improve its anti-tumor-immune response and decrease its …
Authors
Li J; Gyorffy SF; Ring DB; Kwok CS; Austin RC
Journal
Tumor Targeting, Vol. 4, No. 2, pp. 105–114
Publication Date
January 1, 1999
ISSN
1351-8488